Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER-2 Positive Breast Cancer × Docetaxel × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 431 Triple Negative Breast Neoplasms 28 Neoplasms 20 Carcinoma, Non-Small-Cell Lung 20 Breast Neoplasms, Male 19 Neoplasm Metastasis 18 Prostatic Neoplasms 16 Inflammatory Breast Neoplasms 15 HER2-positive Breast Cancer 13 Ovarian Neoplasms 11 Lung Neoplasms 11 Stomach Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 9 Head and Neck Neoplasms 8 Urinary Bladder Neoplasms 7 Melanoma 7 Esthesioneuroblastoma, Olfactory 7 Carcinoma, Renal Cell 7 Small Cell Lung Carcinoma 6 Salivary Gland Neoplasms 6 Pancreatic Neoplasms 6 Neutropenia 6 Esophageal Neoplasms 6 Breast Diseases 6 Sarcoma 4 Primary Breast Cancer 4 Pathologic Complete Response 4 Colonic Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Anatomic Stage I Breast Cancer AJCC v8 4

Interventions

Trastuzumab 2 liposomal doxorubicin 1 eribulin 1 Metformin 1 Doxorubicin 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡